使用表观遗传疗法克服化疗耐药性。
Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
作者信息
Strauss Julius, Figg William D
机构信息
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
出版信息
Anticancer Res. 2016 Jan;36(1):1-4.
It has been known for decades that as cancer progresses, tumors develop genetic alterations, making them highly prone to developing resistance to therapies. Classically, it has been thought that these acquired genetic changes are fixed. This has led to the paradigm of moving from one cancer therapy to the next while avoiding past therapies. However, emerging data on epigenetic changes during tumor progression and use of epigenetic therapies have shown that epigenetic modifications leading to chemotherapy resistance have the potential to be reversible with epigenetic therapy. In fact, promising clinical data exist that treatment with epigenetic agents can diminish chemotherapy resistance in a number of tumor types including chronic myelogenous leukemia, colorectal, ovarian, lung and breast cancer. The potential for epigenetic-modifying drugs to allow for treatment of resistant disease is exciting and clinical trials have just begun to evaluate this area.
几十年来，人们已经知道，随着癌症的进展，肿瘤会发生基因改变，使其极易产生对治疗的耐药性。传统上，人们认为这些获得性基因变化是固定不变的。这导致了一种模式，即从一种癌症治疗转向另一种治疗，同时避免使用过去的治疗方法。然而，有关肿瘤进展过程中表观遗传变化以及表观遗传疗法应用的新数据表明，导致化疗耐药的表观遗传修饰有可能通过表观遗传疗法逆转。事实上，已有有前景的临床数据表明，使用表观遗传药物进行治疗可以降低包括慢性粒细胞白血病、结直肠癌、卵巢癌、肺癌和乳腺癌在内的多种肿瘤类型的化疗耐药性。表观遗传修饰药物治疗耐药疾病的潜力令人兴奋，临床试验刚刚开始评估这一领域。
Zotero 插件